Prevention of bronchial hyperplasia by EGFR pathway inhibitors in an organotypic culture model

Cancer Prevention Research

Volumn 4, Issue 8, 2011, Pages 1306-1315

  Lee, Jangsoon ^a   Ryu, Seung Hee ^a,b   Kang, Shin Myung ^a,c   Chung, Wen Cheng ^a   Gold, Kathryn Ann ^a   Kim, Edward S ^a   Hittelman, Walter N ^a   Hong, Waun Ki ^a   Koo, Ja Seok ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Asan Medical Center   (South Korea)

^c National Cancer Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; AMPHIREGULIN; CYCLIN D1; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN C JUN; PROTEIN KINASE B; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR ALPHA;

ANTIGEN EXPRESSION; ARTICLE; BRONCHIAL EPITHELIUM HYPERPLASIA; CELL PROLIFERATION; EPITHELIUM HYPERPLASIA; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

BRONCHI; BUTADIENES; CELL LINE, TUMOR; CYCLIN D1; ENZYME INHIBITORS; HUMANS; HYPERPLASIA; LUCIFERASES; LUNG NEOPLASMS; MAP KINASE KINASE KINASES; MODELS, BIOLOGICAL; NITRILES; ORGAN CULTURE TECHNIQUES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING;

EID: 80051497164     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0364     Document Type: Article

References (38)

1. Saccomanno G, Archer VE, Auerbach O, Saunders RP, Brennan LM. Development of carcinoma of the lung as reflected in exfoliated cells. Cancer 1974;33:256-70.
2. Auerbach O, Hammond EC, Garfinkel L. Changes in bronchial epithelium in relation to cigarette smoking, 1955-1960 vs. 1970-1977. N Engl J Med 1979;300:381-5.
3. Saccomanno G, Archer VE, Saunders RP, Auerbach O, Klein MG. Early indices of cancer risk among uranium miners with reference to modifying factors. Ann N Y Acad Sci 1976;271:377-83.
4. Strong MS, Incze J, Vaughan CW. Field cancerization in the aerodigestive tract-its etiology, manifestation, and significance. J Otolaryngol 1984;13:1-6.
5. Warburton D, Schwarz M, Tefft D, Flores-Delgado G, Anderson KD, Cardoso WV. The molecular basis of lung morphogenesis. Mech Dev 2000;92:55-81.
6. Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 2004;10:4227s-32s.
7. Vlahovic G, Crawford J. Activation of tyrosine kinases in cancer. The Oncologist 2003;8:531-8.
8. Koo JS, Jetten AM, Belloni P, Yoon JH, Kim YD, Nettesheim P. Role of retinoid receptors in the regulation of mucin gene expression by retinoic acid in human tracheobronchial epithelial cells. Biochem J 1999;338:351-7.
9. Aggarwal S, Kim SW, Cheon K, Tabassam FH, Yoon JH, Koo JS. Nonclassical action of retinoic acid on the activation of the cAMP response element-binding protein in normal human bronchial epithelial cells. Mol Biol Cell 2006;17:566-75.
10. Kim SW, Cheon K, Kim CH, Yoon JH, Hawke DH, Kobayashi R, et al. Proteomics-based identification of proteins secreted in apical surface fluid of squamous metaplastic human tracheobronchial epithelial cells cultured by three-dimensional organotypic air-liquid interface method. Cancer Res 2007;67:6565-73.
11. Koo JS, Yoon JH, Gray T, Norford D, Jetten AM, Nettesheim P. Restoration of the mucous phenotype by retinoic acid in retinoid-deficient human bronchial cell cultures: changes in mucin gene expression. Am J Respir Cell Mol Biol 1999;20:43-52.
12. Loupakis F, Vasile E, Santini D, Masi G, Falcone A, Graziano F. EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach. Pharmacogenomics 2008;9:55-69.
13. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
14. Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997;57:4838-48.
15. Johnson BE. Second lung cancers in patients after treatment for an initial lung cancer. J Natl Cancer Inst 1998;90:1335-45.
16. Gold KA, Lee JJ, Rice D, Tse W, Stewart D, Wistuba I, et al. Phase II pilot study of neoadjuvant docetaxel and cisplatin followed by adjuvant erlotinib in patients with stage I-III non-small cell lung cancer (NSCLC). J Clin Oncol ASCO Annu Meeting Proc (Post-Meeting Ed) 2009;27.
17. Motokura T, Arnold A. Cyclin D and oncogenesis. Curr Opin Genet Dev 1993;3:5-10.
18. Sheyn I, Noffsinger AE, Heffelfinger S, Davis B, Miller MA, Fenoglio-Preiser CM. Amplification and expression of the cyclin D1 gene in anal and esophageal squamous cell carcinomas. Hum Pathol 1997;28:270-6.
19. Bellacosa A, Almadori G, Cavallo S, Cadoni G, Galli J, Ferrandina G, et al. Cyclin D1 gene amplification in human laryngeal squamous cell carcinomas: prognostic significance and clinical implications. Clin Cancer Res 1996;2:175-80.
20. Yatabe Y, Nakamura S, Seto M, Kuroda H, Kagami Y, Suzuki R, et al. Clinicopathologic study of PRAD1/cyclin D1 overexpressing lymphoma with special reference to mantle cell lymphoma. A distinct molecular pathologic entity. Am J Surg Pathol 1996;20:1110-22.
21. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994;54:1812-7.
22. Bartkova J, Lukas J, Strauss M, Bartek J. Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 1995;10:775-8.
23. Reissmann PT, Koga H, Takahashi R, Figlin RA, Holmes EC, Piantadosi S, et al. Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. The Lung Cancer Study Group. Oncogene 1993;8:1913-9.
24. Kratzke RA, Greatens TM, Rubins JB, Maddaus MA, Niewoehner DE, Niehans GA, et al. Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res 1996;56:3415-20.
25. Lonardo F, Rusch V, Langenfeld J, Dmitrovsky E, Klimstra DS. Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. Cancer Res 1999;59:2470-6.
26. Witschi H, Espiritu I, Suffia M, Pinkerton KE. Expression of cyclin D1/2 in the lungs of strain A/J mice fed chemopreventive agents. Carcinogenesis 2002;23:289-94.
27. Boyle JO, Langenfeld J, Lonardo F, Sekula D, Reczek P, Rusch V, et al. Cyclin D1 proteolysis: a retinoid chemoprevention signal in normal, immortalized, and transformed human bronchial epithelial cells. JNatl Cancer Inst 1999;91:373-9.
28. Ratschiller D, Heighway J, Gugger M, Kappeler A, Pirnia F, Schmid RA, et al. Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J Clin Oncol 2003;21:2085-93.
29. Filipits M, Pirker R, Dunant A, Lantuejoul S, Schmid K, Huynh A, et al. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol 2007;25:2735-40.
30. Kobayashi S, Shimamura T, Monti S, Steidl U, Hetherington CJ, Lowell AM, et al. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res 2006;66:11389-98.
31. Petty WJ, Dragnev KH, Memoli VA, Ma Y, Desai NB, Biddle A, et al. Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers. Clin Cancer Res 2004;10:7547-54.
32. Dragnev KH, Petty WJ, Shah SJ, Lewis LD, Black CC, Memoli V, et al. A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer. Clin Cancer Res 2007;13:1794-800.
33. Papadimitrakopoulou V, Izzo JG, Liu DD, Myers J, Ceron TL, Lewin J, et al. Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res 2009;2:14-21.
34. Freemantle SJ, Guo Y, Dmitrovsky E. Retinoid chemoprevention trials: cyclin D1 in the crosshairs. Cancer Prev Res 2009;2:3-6.
35. Takuwa N, Takuwa Y. Ras activity late in G1 phase required for p27kip1 downregulation, passage through the restriction point, and entry into S phase in growth factor-stimulated NIH 3T3 fibroblasts. Mol Cell Biol 1997;17:5348-58.
36. Lavoie JN, LoAllemain G, Brunet A, Muller R, Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 1996;271:20608-16.
37. Lee RJ, Albanese C, Stenger RJ, Watanabe G, Inghirami G, Haines GK, et al. pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells. J Biol Chem 1999;274:7341-50.
38. Han SW, Roman J. Fibronectin induces cell proliferation and inhibits apoptosis in human bronchial epithelial cells: pro-oncogenic effects mediated by PI3-kinase and NF-kappa B. Oncogene 2006;25:4341-9.